NO. 6178 RESPONSE UNDER 37 C.F.K. §1.116 EXPENTED PROCEDURE EXAMINING GROUP 1800

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Baka SOLOMON

Art Unit: 1842

Application No.: 09/441,140

Conf. No. 3910

Examiner: C. Nichols

Filed: November 16, 1999

(Col. 3)

PRESENT

EXTRA

**EQUALS** 

0

Washington, D.C. Atty.'s Docket: SOLOMON=1R

Date: August 18, 2004

THE COMMISSIONER OF PATENTS 2011 South Clark Place, Mail Stop Crystal Plaza Two, Lobby, Room 1803 Arlington, VA 22202 VIA TELEFACSIMILE

OR

OR

RECEIVED CENTRAL FAX CENTER

SIr:

TOTAL

INDEP.

Ţŗ	añ8i	mitted herewith is a ()	G Supplemental Amendment ( ]	
în l	the	above identified appl	cation.	
•	•	Small Entity Status:	Applicant(s) claim small entity status.	See 37 C.F.R. §1.27.

No additional fee is required.

(Col. 1)

CLAIMS

REMAINING

AFTER

AMENDMENT

5

FIRST PRESENTATION OF MULTIPLE DEP. CLAIM

The fee has been calculated as shown below:

For: PREVENTION OF PROTEIN AGGREGATION

SMALL ENTITY			
	RATE	ADDITIONAL FEE	
х	9	5	
×	43	\$	
Ē.	145	2	

ADDITIONAL FEE TOTAL \_\_\_\_\_\_\_\_

OTHER THAN	SMALL ENTITY
RATE	ADDITIONAL FEE
x 18	S
x 86 x	\$
± 290	\$
TOTAL	\$

If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

MINUS

MINUS

- If the "Highest Number Previously Peld for" IN THIS SPACE is less than 20, write "20" in this apace.
- If the "Highest Number Previously Paid for IN THIS SPACE is less than 3, write "3" in this space.

(Col. 2)

HIGHEST NO.

PREVIOUSLY

PAID FOR

26

The "Highest Number Previously Paid For" (total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[DOX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[ ] It is hereby petitioned for an extension of time in accordance with 37 CFR 1,138(a). The appropriate fee required by 37 CFR 1,17 is calculated as shown below:

	Small Entity			V	HIBI I	Han Sinan	Lilly	y	
	Response Filled Within			Response Filed Within					
	[ ] First	- \$ 55,00		Į	)	First	-	\$	110.00
	[ ] Second	- \$ 210.00		I	3	Second	~	\$	420.00
	[ ] Third	- \$ 475,00		Į.	}	Third	•	5	950.00
	[ ] Fourth	- \$ 740.00		ĭ	3	Fourth	-	\$	1480.00
	Month After Time	e Period Set		N.	onth.	After Time i	Peri	od S	iet
( 1			pald for month(s) extends  Io. 02-4035 in the amount	•					
[ ]	Credit Card Payn	nent Form, PTO-203	38, is attached, authorizing	payment in the am	อนกt a	of S.			
1 }	A check in the ar	mount of \$	is attached (check	no, ).					
[XX]			eed and requested to char 02-4035. This authorizati						

nection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not infled to payment of all fees associated with this communication, including any Extension of Time (e.g., not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.19 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Altomeys for Applicant(s)

Roger L. Browdy Registration No. 25,618

acsimile: (202) 737-3528 Telephone: (202) 628-5197

## RESPONSE UNDER 37 C.F.R. §1.116 EXPEDITED PROCEDURE EXAMINING GROUP 1600

IN THE UNITED STATES	PATENT AND TRADEMARK OFFICE	RECEIVED CENTRAL FAX CENTER
114 200	Atty. Docket: SOLOMON=1R	AUG 1 8 2004
In re Application of:	) Conf. No.: 3910	<b>A B B B A A A A A A B B A B A B A B A B A B B A</b>
Beka SOLOMON	Art Unit: 1647	()FFICIAI
Appln. No.: 09/441,140	) Examiner: C. Nichols	
Filed: November 16, 1999	) Washington, D.C.	
For: PREVENTION OF PROTEIN AGGREGATION	) August 18, 2004 )	

## SUPPLEMENTAL AMENDMENT

U.S. Patent and Trademark Office 2011 South Clark Place Customer Window, Mail Stop Amendment Non-Fee Crystal Plaza Two, Lobby, Room 1803 Arlington, Virginia 22202

Sir:

Supplementing applicant's Amendment of August 9, 2004, please amend as follows:

IN THE CLAIMS
Please insert new claims 168-172 as follows:
168. A pharmaceutical formulation, comprising:
(A) an antibody or antigen binding fragment thereof,
wherein:
(i) said antibody is obtainable using residues
1-28 of beta-amyloid as an immunogen, and
(ii) said antibody and said fragment maintain
the solubility of soluble beta-amyloid; and
(B) a pharmaceutically acceptable carrier.